{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:25:42Z","timestamp":1791689142919,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation in Shaanxi Province","award":["2023-JC-QN-0890"],"award-info":[{"award-number":["2023-JC-QN-0890"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC 81202014"],"award-info":[{"award-number":["NSFC 81202014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Research and Development Program of Shaanxi Province","award":["2022SF-307"],"award-info":[{"award-number":["2022SF-307"]}]},{"name":"the Fundamental Research Funds for the Central Universities"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13482-9","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:25:00Z","timestamp":1738581900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of 18F-PSMA-1007 PET\/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Junjie","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangdong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaosheng","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyuan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"1","key":"13482_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate Cancer incidence and mortality rates. Eur Urol. 2020;77(1):38\u201352.","journal-title":"Eur Urol"},{"key":"13482_CR2","unstructured":"Prostate Cancer. [https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470550\/]."},{"issue":"3","key":"13482_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","volume":"124","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124(3):401\u20137.","journal-title":"BJU Int"},{"issue":"8","key":"13482_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00345-022-04134-9","volume":"41","author":"N Matsumura","year":"2023","unstructured":"Matsumura N, Fujita K, Nishimoto M, Minami T, Tahara H, Yoshimura K, Uemura H. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer. World J Urol. 2023;41(8):2063\u20138.","journal-title":"World J Urol"},{"issue":"11","key":"13482_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer: long-term survival analysis of the Randomized Phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"issue":"7069","key":"13482_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820\u20137.","journal-title":"Nature"},{"issue":"6","key":"13482_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2008.04.045","volume":"133","author":"SS McAllister","year":"2008","unstructured":"McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994\u20131005.","journal-title":"Cell"},{"issue":"3","key":"13482_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar R, Verhagen P, van Andel G. Effect on survival of androgen deprivation therapy alone compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the prostate in patients with primary bone metastatic prostate Cancer in a prospective Randomised Clinical Trial: data from the HORRAD Trial. Eur Urol. 2019;75(3):410\u20138.","journal-title":"Eur Urol"},{"issue":"10162","key":"13482_CR9","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366.","journal-title":"Lancet"},{"key":"13482_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","volume":"29","author":"N Lumen","year":"2021","unstructured":"Lumen N, De Bleser E, Buelens S, Verla W, Poelaert F, Claeys W, Fonteyne V, Verbeke S, Villeirs G, De Man K, et al. The role of Cytoreductive Radical Prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate Cancer. Results from the local treatment of metastatic prostate Cancer (LoMP) Registry. Eur Urol open Sci. 2021;29:68\u201376.","journal-title":"Eur Urol open Sci"},{"issue":"1","key":"13482_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","volume":"130","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran P, Wilson C, Rombach I, Hassanali N, Aning J, A DL, Cathcart P, Eden C, Ahmad I, Rajan P, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-metastases to the bone (TRoMbone) trial. BJU Int. 2022;130(1):43\u201353.","journal-title":"BJU Int"},{"key":"13482_CR12","doi-asserted-by":"crossref","unstructured":"Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, Krzywon A, Miszczyk M, Moll M, Stando R, et al. Outcomes of Cytoreductive Radical Prostatectomy for oligometastatic prostate Cancer on prostate-specific membrane Antigen Positron Emission Tomography: results of a Multicenter European Study. Eur Urol Oncol; 2023.","DOI":"10.1016\/j.euo.2023.09.006"},{"issue":"4","key":"13482_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226\u201335.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"13482_CR14","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D, B\u00e4uerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, et al. (68)Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1862\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"13482_CR15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T. Initial experience with volumetric (68)Ga-PSMA I&T PET\/CT for Assessment of Whole-Body Tumor Burden as a quantitative imaging biomarker in patients with prostate Cancer. J Nucl Med. 2017;58(12):1962\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"13482_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","volume":"62","author":"F Barbato","year":"2021","unstructured":"Barbato F, Fendler WP, Rauscher I, Herrmann K, Wetter A, Ferdinandus J, Seifert R, Nader M, Rahbar K, Hadaschik B, et al. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med. 2021;62(12):1747\u201350.","journal-title":"J Nucl Med"},{"issue":"8","key":"13482_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","volume":"63","author":"QA Shagera","year":"2022","unstructured":"Shagera QA, Artigas C, Karfis I, Critchi G, Chanza NM, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P. (68)Ga-PSMA PET\/CT for Response Assessment and Outcome Prediction in metastatic prostate Cancer patients treated with taxane-based chemotherapy. J Nucl Med. 2022;63(8):1191\u20138.","journal-title":"J Nucl Med"},{"issue":"9","key":"13482_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/RLU.0000000000004763","volume":"48","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, Karfis I, Sideris S, Guiot T, Woff E, Martinez-Chanza N, Roumeguere T, Gil T, Flamen P, Artigas C. Tumor volume on PSMA PET as a prognostic biomarker in prostate Cancer patients treated with Cabazitaxel. Clin Nucl Med. 2023;48(9):775\u201380.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"13482_CR19","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s00259-023-06163-x","volume":"50","author":"M Kim","year":"2023","unstructured":"Kim M, Seifert R, Fragemann J, Kersting D, Murray J, Jonske F, Pomykala KL, Egger J, Fendler WP, Herrmann K, et al. Evaluation of thresholding methods for the quantification of [(68)Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [(177)Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50(7):2196\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"13482_CR20","doi-asserted-by":"crossref","unstructured":"Cardinale J, Martin R, Remde Y, Sch\u00e4fer M, Hienzsch A, H\u00fcbner S, Zerges AM, Marx H, Hesse R, Weber K et al. Procedures for the GMP-Compliant production and Quality Control of [(18)F]PSMA-1007: a Next Generation Radiofluorinated Tracer for the detection of prostate Cancer. Pharmaceuticals (Basel) 2017, 10(4).","DOI":"10.3390\/ph10040077"},{"issue":"5","key":"13482_CR21","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"13482_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.urology.2017.02.051","volume":"106","author":"F Poelaert","year":"2017","unstructured":"Poelaert F, Verbaeys C, Rappe B, Kimpe B, Billiet I, Plancke H, Decaestecker K, Fonteyne V, Buelens S, Lumen N. Cytoreductive prostatectomy for metastatic prostate Cancer: First lessons learned from the multicentric prospective local treatment of metastatic prostate Cancer (LoMP) trial. Urology. 2017;106:146\u201352.","journal-title":"Urology"},{"issue":"6","key":"13482_CR23","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058\u201366.","journal-title":"Eur Urol"},{"issue":"5","key":"13482_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.eururo.2015.05.023","volume":"69","author":"P Sooriakumaran","year":"2016","unstructured":"Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, et al. A multi-institutional analysis of Perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate Cancer at Presentation. Eur Urol. 2016;69(5):788\u201394.","journal-title":"Eur Urol"},{"key":"13482_CR25","doi-asserted-by":"publisher","first-page":"879089","DOI":"10.3389\/fonc.2022.879089","volume":"12","author":"S Zschaeck","year":"2022","unstructured":"Zschaeck S, Andela SB, Amthauer H, Furth C, Rogasch JM, Beck M, Hofheinz F, Huang K. Correlation between quantitative PSMA PET parameters and clinical risk factors in non-metastatic primary prostate Cancer patients. Front Oncol. 2022;12:879089.","journal-title":"Front Oncol"},{"issue":"9","key":"13482_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kr\u00f6nke M, Tetteh G, Navarro F, Wang H, G\u00fcnther E, Menze B, Weber WA, Eiber M. qPSMA: Semiautomatic Software for whole-body tumor Burden Assessment in prostate Cancer using (68)Ga-PSMA11 PET\/CT. J Nucl Med. 2019;60(9):1277\u201383.","journal-title":"J Nucl Med"},{"issue":"12","key":"13482_CR27","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Sch\u00e4fers M, Shah V, Xu Z, Chabin G, Grbic S, Spottiswoode B, Rahbar K. Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a Biomarker for Survival in patients with advanced prostate Cancer. J Nucl Med. 2020;61(12):1786\u201392.","journal-title":"J Nucl Med"},{"issue":"1","key":"13482_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2967\/jnumed.123.266158","volume":"65","author":"K Kluge","year":"2024","unstructured":"Kluge K, Einspieler H, Haberl D, Spielvogel C, Stoiber S, Vraka C, Papp L, Wunsch S, Egger G, Kramer G, et al. Examining the relationship and prognostic significance of cell-free DNA levels and the PSMA-Positive tumor volume in men with prostate Cancer: a retrospective-prospective [(68)Ga]Ga-PSMA-11 PET\/CT study. J Nucl Med. 2024;65(1):63\u201370.","journal-title":"J Nucl Med"},{"issue":"2","key":"13482_CR29","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/curroncol30020170","volume":"30","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa T, Rajwa P, Kawada T, Bekku K, Laukhtina E, Deimling MV, Majdoub M, Chlosta M, Karakiewicz PI, Heidenreich A, et al. An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for metastatic prostate Cancer. Curr Oncol (Toronto Ont). 2023;30(2):2194\u2013216.","journal-title":"Curr Oncol (Toronto Ont)"},{"issue":"1","key":"13482_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13014-024-02483-w","volume":"19","author":"S Bela Andela","year":"2024","unstructured":"Bela Andela S, Amthauer H, Furth C, Rogasch JM, Beck M, Mehrhof F, van den Ghadjar P, Klatte T, Tahbaz R, et al. Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value. Radiation Oncol (London England). 2024;19(1):97.","journal-title":"Radiation Oncol (London England)"},{"issue":"8","key":"13482_CR31","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1007\/s00432-022-04438-8","volume":"149","author":"ZB Ke","year":"2023","unstructured":"Ke ZB, Chen JY, You Q, Sun JB, Xue YT, Ye XJ, Chen SH, Xue XY, Sun XL, Chen DN, et al. Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage. J Cancer Res Clin Oncol. 2023;149(8):5071\u201384.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"13482_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","volume":"20","author":"MJ Roberts","year":"2023","unstructured":"Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, Siva S, Hofman MS, Murphy DG, Emmett L, et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023;20(1):23\u201347.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"13482_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"13482_CR34","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2967\/jnumed.121.263139","volume":"63","author":"MJ Hagens","year":"2022","unstructured":"Hagens MJ, Oprea-Lager DE, Vis AN, Wondergem M, Donswijk ML, Meijer D, Emmett L, van Leeuwen PJ. Reproducibility of PSMA PET\/CT imaging for primary staging of Treatment-Na\u00efve prostate Cancer patients depends on the Applied Radiotracer: a retrospective study. J Nucl Med. 2022;63(10):1531\u20136.","journal-title":"J Nucl Med"},{"issue":"2","key":"13482_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/bju.15632","volume":"130","author":"BL van der Heesterman","year":"2022","unstructured":"van der Heesterman BL, Schoots IG, Mehra N, Aben KKH. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. BJU Int. 2022;130(2):217\u201325.","journal-title":"BJU Int"},{"issue":"1","key":"13482_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13550-023-01009-x","volume":"13","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Fan J, Gan C, Dong X, Gao G, Wang Z, He D, Li L, Duan X, Wu K. Impact of non-regional lymph node metastases accurately revealed on (18)F-PSMA-1007 PET\/CT in the clinical management of metastatic hormone-sensitive prostate cancer. EJNMMI Res. 2023;13(1):64.","journal-title":"EJNMMI Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13482-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13482-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13482-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:25:11Z","timestamp":1738581911000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13482-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13482"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13482-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study and involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This retrospective analysis was approved by the Institutional Review Board of the First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, P.R. China. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this study and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}